RTTNews | Dec 22, 2020 06:43AM EST

06:42 Tuesday, December 22, 2020 (RTTNews.com) - CytoDyn Inc. (CYDY) said a treating physician has received authorization from the FDA to administer leronlimab for a COVID-19 patient under emergency IND. CytoDyn said FDA's decision will enable it to respond to ongoing requests for leronlimab until phase 3 trial data is unblinded.

Nader Pourhassan, CEO of CytoDyn, stated: "We are very thankful the FDA is allowing severe-to-critical COVID-19 patients access to Vyrologix (leronlimab) again under eIND while we await the unblinding of data from our recently completed phase 3 registrational trial."

Read the original article on RTTNews ( https://www.rttnews.com/3155578/cytodyn-fda-allows-severe-to-critical-covid-19-patients-access-to-leronlimab-again-under-eind.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2020 RTTNews.com All Rights Reserved